Indian stocks: Visit www.stage2stocks.com →

Boundless Bio, Inc.

Stage 3 · Topping · week 1

As of Oct 22, 2026, Boundless Bio is in Stage 3, the topping phase, now in its first week (since Oct 20, 2026). It closed at $2.44, 18.7% below its 52-week high and above its 200-day average, which is rising.

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. More about the company

$2.44
+0.00% today
$56.4M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is BOLD early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2024-03-28 → 2026-10-22
S? 42w
S4 33w
S1 14w
S4 18w
S2 26w
2024-03-282026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w → S4 33w → S1 14w → S4 18w → S1 1w → S2 26w → S3 1w current
Total tracked: 134 weeks across 7 stage runs.

BOLD among Biotechnology76th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…76BOLDStage 3 · wk 190−9.6%
vs 52W High
-18.7%
$1.05 lo$3.00 hi
18.7% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 1
1w13w26w
Week 1, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
30.0%
200 DMA: $1.88 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.76x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-9.6%
3M
-5.1%
6M
+60.5%
YTD
+100.0%
1Y
+63.8%
Scan Membership
Not in any current scan.
Recent Stage Timeline
2026-10-22S3
Wk 1 · Vol 0.76x
2026-10-21S3
Wk 1 · Vol 0.39x
2026-10-20S32→3
Wk 1 · Vol 0.52x
2026-10-19S2
Wk 25 · Vol 1.24x
2026-10-16S2
Wk 25 · Vol 4.21x
2026-10-15S2
Wk 25 · Vol 1.03x
2026-10-14S2
Wk 25 · Vol 0.72x
2026-10-13S2
Wk 24 · Vol 2.60x
2026-10-12S2
Wk 24 · Vol 0.34x
2026-10-09S2
Wk 24 · Vol 0.94x
2026-10-08S2
Wk 24 · Vol 1.94x
2026-10-07S2
Wk 24 · Vol 0.68x
Moving averages & range
50 DMA
$2.71
200 DMA
$1.88
52W High
$3.00
52W Low
$1.05
5D Low
$2.31
Resistance levels (recent highs)
20d High
$2.66
60d High
$3.00
120d High
$3.00
250d High
$3.00
Next resistance
+9.0%
to 20d High
ROE
-67.9%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.8

Boundless Bio: quick answers

What stage is Boundless Bio in?

As of Oct 22, 2026, Boundless Bio (BOLD) is in Stage 3, the topping phase. It entered Stage 3 on Oct 20, 2026 and is in its first week there. What the four stages mean

Is Boundless Bio in an uptrend?

Its uptrend has stalled. Boundless Bio is in Stage 3, the topping phase that follows an advance. It trades 30.0% above its 200-day average, which is rising.

How far is Boundless Bio from its 52-week high?

Boundless Bio closed at $2.44 on Oct 22, 2026, 18.7% below its 52-week high of $3.00. Its 52-week low is $1.05.

How has Boundless Bio performed over the past year?

As of Oct 22, 2026, Boundless Bio is up 63.8% over the past year and up 100.0% so far in 2026.

Which sector and industry is Boundless Bio in?

Boundless Bio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.